#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Immunodeficiency common variable Neuroendocrine carcinoma of the skin Chronic graft versus host disease in skin Hepatocellular carcinoma Cardiomyopathy Focal segmental glomerulosclerosis Gastroenteropancreatic neuroendocrine tumour disease Congenital generalised lipodystrophy Microscopic polyangiitis Infective uveitis Glomerulonephritis membranoproliferative Exudative retinopathy Congenital megacolon Von Hippel-Lindau disease Immune-mediated enterocolitis More trials…

    Learn about Rare Diseases

    Acquired haemophilia – Treatment Short-bowel syndrome IgA nephropathy – Diagnostics Chordoma – Trials in Disease Lysosomal storage disorder – Trials in Disease Congenital nephrogenic diabetes insipidus – Treatment Proteus syndrome Piriformis syndrome Haemophilia A with anti factor VIII – Trials in Disease Loeys-Dietz syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sodium Phenylbutyrate Iptacopan Hydrochloride Colestyramine Mebeverine Hydrochloride Botaretigene Sparoparvovec Inebilizumab Volixibat Kk8123 Cerebrolysin Concentrate Serpina1(Human)-Aav8-1 CAL101 Nitrofurantoin Mogamulizumab Lovastatin Molgramostim L-ALANINE L-Tryptophan Venglustat Munc-Cd34 RNMB3 More therapies…

    Learn about Your Condition

    Trigeminal neuralgia Carotid artery stenosis Fatty acid oxidation disorder Angelman's syndrome Head and neck cancer Psychological trauma Peripheral artery restenosis Ureteric cancer Breast angiosarcoma Epithelioid sarcoma Diverticulitis Gastrooesophageal cancer Osteochondrodysplasia Delayed graft function Thrombosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Laiko General Hospital Of Athens

Laiko General Hospital Of Athens

Messogion Avenue 154, Athens, 115 27, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • Study of icotrokinra for adults with moderately to severely active Crohn’s disease

    Recruiting

    4 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Durvalumab
    • Nivolumab
    Austria Belgium Denmark France Germany Greece +6

  • A Study of Gilteritinib to Eliminate Remaining Cancer Cells in Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Gilteritinib
    Greece

  • A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST PD-L1 CONJUGATED TO MONOMETHYL AURISTATIN E VIA A VALINE-CITRULLINE LINKER
    • Docetaxel
    Belgium Bulgaria Czechia Denmark Finland France +8

  • A Study Testing Imeroprubart for Adults with Primary Sjogren’s Disease with Moderate to Severe Symptoms

    Recruiting

    2 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • IMEROPRUBART
    Germany Greece Hungary Italy Poland Romania +1

  • A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    • Amivantamab
    • Lazertinib
    Belgium Finland France Germany Greece Italy +3

  • A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Mk-1084
    Austria Belgium France Germany Greece Hungary +5

  • A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Erdafitinib
    • Mitomycin
    • Gemcitabine Hydrochloride
    Belgium France Germany Greece Italy The Netherlands +1

  • A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

    Recruiting

    4 1 1
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Czechia Denmark France +9
Previous Page
1 … 4 5 6 7 8 … 38
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!